Steroids for Early Treatment of Radiation Retinopathy

Withdrawn before enrolling · Phase 2/Phase 3

Conditions studied: Radiation Retinopathy

In brief

Radiation retinopathy is a known complication of ocular radiation therapy. To date there is no known effective treatment. In addition to their anti-vascular endothelial growth factor (VEGF) properties, corticosteroids decrease the retinal capillary permeability by increasing the activity/density of tight junctions and acute inflammatory effects of radiation in various tissues.

Key facts

Study ID

NCT03238157

Run by

The Cleveland Clinic

People needed

0

Starts

2022-02-01

Expected to finish

2022-09-01

Last updated by the study team

2021-08-04

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary uveal melanoma
• Primary treatment with plaque brachytherapy
• Baseline visual acuity 20/200 or better
• Posterior tumor margin >1.50 mm from the center of the macula
• Posterior tumor margin > 1.50 mm from the closest disc margin
• Calculated total dose to center of the macula >40 Gy

You may not qualify if…

• Iris melanoma
• Opaque media
• less than 21 years of age
• Inability to give consent
• Positive pregnancy test

Where it is running

• Cole Eye Instiute — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.